PTPN23

Across TCGA pan-cancer cohorts, PTPN23 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PTPN23 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher PTPN23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPN23 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

PAAD, STAD, and READ are the cancer types where PTPN23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.011	0.641	<.001	24	view →
STAD	OS	Median	All	1.000	0.674	.007	23	view →
READ	DFS	Median	All	0.182	0.798	.010	9	view →
BLCA	OS	Median	III,IV	0.141	0.581	.011	9	view →
SKCM	DFS	Median	III,IV	0.201	0.607	.003	7	view →
UVM	OS	Median	All	0.292	0.674	.035	6	view →
BRCA	DFS	Median	II,III,IV	0.134	0.519	.013	4	view →
LIHC	OS	Median	II,III,IV	0.152	0.614	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PTPN23–PAAD (OS)

Open the PAAD breakdown →